REGiMMUNE to present GvHD data at the 50th ASH Annu... ( Mountain View CA December 5 2008 R...)

REGiMMUNE to present GvHD data at the 50th ASH Annual Meeting

Date:12/5/2008

Mountain View, CA December 5, 2008 REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, will present preclinical data on the company's potential therapeutic treatment for Graft versus Host Disease (GvHD) at the American Society of Hematology Annual Meeting being held December 6 through 9 in San Francisco, California. REGiMMUNE is developing KRN7000 (RGI-2001) as a new immunosuppressant for GvHD associated with stem cell transplantation. Two posters will be presented at ASH on the evenings of Sunday December 7 and Monday December 8, respectively.

Abstract/Poster II-426
Sunday, December 7: 6:00 PM - 8:00 PM
Donor-Specific Tolerance Induction through Expansion of DCregs and Tregs by a Liposomal Formulation of KRN7000 (RGI-2001)

Abstract/Poster III-582
Monday, December 8: 5:30 PM - 7:30 PM
A Liposomal Formulation of KRN7000 (RGI-2001) Potently Reduces GvHD Lethality through the Expansion of CD4+Foxp3+ Regulatory T cells in Murine Models.

"We are delighted to present our progress on RGI-2001 development at the 50th ASH Annual Meeting," said Mr. Haru Morita, President and Chief Executive Officer, REGiMMUNE. "This is a great opportunity to provide an update on our pre-IND stage product candidate, RGI-2001, which is in a preclinical study for GvHD associated with bone marrow transplantation. The company is also developing RGI-2001 for solid organ transplantation. Our mission is to develop novel therapies for immune disorders including allergies, autoimmune diseases and transplantation. We believe the success of RGI-2001 will be the first demonstration of the promise of our proprietary technology and of the company's significant development capabilities."

'/>"/>

Contact: Debra Bannister
530-676-8001
REGiMMUNE
Source:Eurekalert

0

GOOD

Post Your Comments:

(Date:11/5/2009)...ociation and Zinedine Zidane, its emblematic ambas...e results regaring the gene therapy in adrenoleuko...shed in the prestigious journal Science. Two child... halted. The children are doing well, which is une...w months. This discovery opens up treatment perspe...

(Date:11/5/2009)...K, Nov. 5 Wolters Kluwer Health ha...MSN, RN, CRNP, ANP-BC, to the new position of Chie...e nursing strategy of its Lippincott Williams &... leading international publisher of medical and nu...ronic medical, scientific, and academic informatio...

(Date:11/5/2009)...CSBURG, Pa., Nov. 5 Sele... SEM ), the parent of Select Medical Corporation, ...d September 30, 2009. ,, For the third quarter ...ncreased 5.1% to $545.6 million compared to $519.2... from operations decreased 9.0% to $32.9 million c...

(Date:11/5/2009)...BROKE, Bermuda, Nov. 5 A... AWH ) today reported net income of $200.6 millio...er of 2009 compared to a net,loss of $46.4 million...r of,2008. Net income for the nine months ended S... diluted share, compared to net income of,$163.8 m...

(Date:11/5/2009)...ELES, Nov. 5 Narconon Internationa...ts drug rehabilitation and education centers throu...th thousands of students and other community membe...ly Partnership,s (NFP) Red Ribbon Week is consider...tivities and is held during the end of October eac...

[0] 2 children suffering from adrenoleukodystrophy saved thanks to the ELA Association [1] Wolters Kluwer Health Appoints Anne Woods to Chief Nursing Officer; Strengthens Its Commitment to the Nursing Market [1] Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 [0] Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced [0] Narconon Centers Educate Thousands During Red Ribbon Week

...ion (FDA) and Roxane Labs have issued a nationwide...ed in patients with severe// rheumatoid arthritis ...t rejection. "It was discovered that a single...bottle, which was not dispensed to a patient, the ...

...sung has developed a device that can measures body... electrodes that the user touches with the thumb a...ent through the body, measuring the voltage drop a...ult diseases. Since fat occupies 17 percent...

...e treatment of recurrent ovarian cancer ignoring t...mzar in combination with carboplatin (chemotherapy...n cancer. The drug Gemzar also known by its gener...ncer Society about 22,000 women are diagnosed with...

... are two of the main causes of growing infertility...s unable to conceive// normally. "Worldwide...iving. About 50 percent of the infertility problem...noted infertility specialist Rajeev Agarwal. ...

... a memorandum of understanding (MOU) with the Clin... the supply of affordable//, high- quality drugs a...are. The MoU was signed at the Presidential Vi...agreement, Nigeria is to be included in the Clinto...

... of Health (MOH) says that Singapore will soon con... Pandemic Readiness.// More than 1,000 pers...e MOH, the Ministry of Education, the Civil Aviati...I. The two-day emergency exercise endeavors...

Other Medicine News:Health News:Stress and Pollution are Major Cause of Infertility Among Urban Couples 2

Azathioprine 50mg Pills Recalled By FDA And Roxane Labs Samsung Develops Device to Measure Body Fat Gemzar the New Drug for Recurrent Ovarian Cancer Stress and Pollution are Major Cause of Infertility Among Urban Couples MoU for HIV/AIDS Signed by Nigeria and Clinton Foundation Singapore Gears Up To Tackle Bird Flu

(Date:11/5/2009)...Nov. 5 Virtual Health Te...ced today that it has entered into a Letter of Int...d Management Technologies, Inc. (WNDM). The deal p... debt, 4,000,000 shares of WNDM stock and a royalt...closed at $2.00 per share on 11/4/09 and VHGI clos...

(Date:11/5/2009)...SCO, Calif., Nov. 5 Sune...nnounced that the U.S. Food and Drug Administratio...r the treatment of acute myeloid leukemia (AML). S...l trials of voreloxin in AML: a single-agent study...ed elderly AML patients unlikely to benefit from s...

(Date:11/5/2009).... 5 Transgenomic, Inc. (...Webcast: , , What: Transgenomic, Inc. Thir...erence Call, When: Thursday, November 5, 2...tp://www.transgenomic.com/events.asp?id=6, targe...ts.asp?id=6,>http://www.transgenomic.com/events....

Breaking Medicine Technology:OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010 2 OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010 3 Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 2 Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 3 Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast 2 The Lustgarten Foundation Says Patrick Swayzes Death Highlights the Need for Increased Research into Early Diagnosis and Treatment of Pancreatic Cance 57253 1 The Lustgarten Foundation Says Patrick Swayzes Death Highlights the Need for Increased Research into Early Diagnosis and Treatment of Pancreatic Cance 57253 2 Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects New Report Says 5006 1 Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects New Report Says 5006 2 Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects New Report Says 5006 3 Anxious Kids at Risk for Obesity in Adulthood 57251 1 Anxious Kids at Risk for Obesity in Adulthood 57251 2

[0] OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010 [0] Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia [0] Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast

...mary Endpoints Achieved for SCOLR,s 12-Hour ..., Nov. 7 SCOLR Pharma, Inc.,(Amex: DDD ) today r...onths,ended September 30, 2008. The Company will h..., at 11:30 a.m. (Eastern Standard Time)., Daniel ..."We had a very,productive third quarter making sig...

...Pharmaceuticals,Inc. (Nasdaq: CADX ), a biopharma...g and commercializing proprietary product candidat...day reported financial results for the,third quart... company also provided an update on the clinical d...candidates -- Acetavance(TM), an,intravenous formu...

SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update

...ontinuous random access capabilities to immunodiag...d, anemia, cardiac, reproductive, endocrinology, o...available, with infectious disease assays under de...ss 60 accessible samples for a throughput of 90 pa...

Myoglobin IRMA Kit

...r the quantitative determination of prolactin in h...and treatment of disorders of the anterior pituita...tative Test is based on the principle of a solid p...system utilized sheep anti-prolactin for solid pha...

Prolactin Radioimmunoassay

Medicine Products:

Myoglobin Assay for the VITROS ECi Immunodiagnostic System Myoglobin IRMA Kit BioCheck Prolactin Enzyme Immunoassay Prolactin Radioimmunoassay

REGiMMUNE to present GvHD data at the 50th ASH Annu...( Mountain View CA December 5 2008 R...),Health